Clinical trial
Vaccine Therapy in Treating Patients With Stage IV Melanoma
NCT00003665 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00003665 |
|---|---|
| Title | Vaccine Therapy in Treating Patients With Stage IV Melanoma |
| Official title | Phase I Trial of a Dendritic Cell Vaccine for Melanoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Biological |
| Interventions | dendritic cell-MART-1 peptide vaccine, gp100 antigen, therapeutic tumor infiltrating lymphocytes, tyrosinase peptide |
| Enrollment | 40 |
| Start date | Apr 1, 1999 |
| Primary completion | Oct 1, 2002 |
| Completion | Nov 1, 2002 |
| First posted | Feb 9, 2004 |
| Last update posted | Feb 28, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: